STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 3] Relay Therapeutics, Inc. Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3
Rhea-AI Filing Summary

Relay Therapeutics (RLAY)Director.

The filing states that no securities are beneficially owned. It indicates the form was filed by one reporting person and includes a power of attorney authorization. This is an administrative disclosure and does not report any transactions.

Positive
  • None.
Negative
  • None.
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Dable Habib J

(Last) (First) (Middle)
C/O RELAY THERAPEUTICS, INC.
60 HAMPSHIRE STREET

(Street)
CAMBRIDGE MA 02139

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
11/04/2025
3. Issuer Name and Ticker or Trading Symbol
Relay Therapeutics, Inc. [ RLAY ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
Exhibit 24 - Power of Attorney
No securities are beneficially owned.
/s/ Soo-Yeun Lim, as Attorney-in-Fact 11/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Relay Therapeutics (RLAY) file?

A Form 3, the initial statement of beneficial ownership under Section 16.

Who is the reporting person in this RLAY Form 3?

The person is identified as a Director of Relay Therapeutics.

How many RLAY shares does the director report owning?

The filing states no securities are beneficially owned.

Is there any transaction reported in this Form 3?

No. This is an administrative ownership disclosure; it reports no transactions.

Was the filing submitted by one or multiple reporting persons?

It was filed by one reporting person.

What supporting authorization is included?

The filing includes Exhibit 24 - Power of Attorney.
Relay Therapeutics, Inc.

NASDAQ:RLAY

RLAY Rankings

RLAY Latest News

RLAY Latest SEC Filings

RLAY Stock Data

1.13B
140.88M
1.42%
100.37%
13.18%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE